Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayhyun Seo

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancers|January 11, 2025
A Narrative Review of the Assessment and Treatment of Physical Impairments Commonly Seen in Sarcoma Cancer Survivors Using a Rehabilitative ApproachAdrian Cristian, Nandita Keole, Romer Orada, et al.
Journal of Patient-Centered Research and Reviews|February 1, 2020
Surgeons' Views on Shared Decision-MakingSuraj Kannan, Jayhyun Seo, Kevin R Riggs, et al.
Journal of the American Academy of Dermatology|May 27, 2023
Underuse of sentinel lymph node biopsy for early-stage melanomaAhmad Rajeh, Guihong Wan, Katie Roster, et al.
Scientific Reports|September 23, 2018
Biomechanical interplay between anisotropic re-organization of cells and the surrounding matrix underlies transition to invasive cancer spreadDeok-Ho Kim, Andrew J Ewald, JinSeok Park, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort studyBruce C Tiu, Leyre Zubiri, James Iheke, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
The Lancet. Oncology|July 18, 2024
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort studyGuihong Wan, Wenxin Chen, Sara Khattab, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancers|January 11, 2025
A Narrative Review of the Assessment and Treatment of Physical Impairments Commonly Seen in Sarcoma Cancer Survivors Using a Rehabilitative ApproachAdrian Cristian, Nandita Keole, Romer Orada, et al.
Journal of Patient-Centered Research and Reviews|February 1, 2020
Surgeons' Views on Shared Decision-MakingSuraj Kannan, Jayhyun Seo, Kevin R Riggs, et al.
Journal of the American Academy of Dermatology|May 27, 2023
Underuse of sentinel lymph node biopsy for early-stage melanomaAhmad Rajeh, Guihong Wan, Katie Roster, et al.
Scientific Reports|September 23, 2018
Biomechanical interplay between anisotropic re-organization of cells and the surrounding matrix underlies transition to invasive cancer spreadDeok-Ho Kim, Andrew J Ewald, JinSeok Park, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort studyBruce C Tiu, Leyre Zubiri, James Iheke, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
The Lancet. Oncology|July 18, 2024
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort studyGuihong Wan, Wenxin Chen, Sara Khattab, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 1